A combination therapy for treating advanced cancer, comprises, first, performing targeted low dose radiation therapy on a recipient tumoral site to generate an inflammation zone and an immuno-stimulant effect, including release of cytokines and chemokines. Secondly, PMBC collected from a suitable donor are administered intravenously in order to initiate an allogeneic reaction. The post-radiotherapy inflammation zone will attract the newly injected PBMC to the tumor bed, triggering an immunological cancer cell rejection. The cellular response in the recipient is monitored and post-treatment evaluation for recipients side effects is also provided.
